Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 143


Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options.

Ang C, Miura JT, Gamblin TC, He R, Xiu J, Millis SZ, Gatalica Z, Reddy SK, Yee NS, Abou-Alfa GK.

J Surg Oncol. 2016 Jan;113(1):55-61. doi: 10.1002/jso.24086. Epub 2015 Dec 10.


Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast.

Gatalica Z, Vranic S, Ghazalpour A, Xiu J, Ocal IT, McGill J, Bender RP, Discianno E, Schlum A, Sanati S, Palazzo J, Reddy S, Pockaj B.

Oncotarget. 2015 Nov 28. doi: 10.18632/oncotarget.6421. [Epub ahead of print]


Molecular profiling of head and neck squamous cell carcinoma.

Feldman R, Gatalica Z, Knezetic J, Reddy S, Nathan CA, Javadi N, Teknos T.

Head Neck. 2015 Nov 28. doi: 10.1002/hed.24290. [Epub ahead of print]


Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.

El-Deiry WS, Vijayvergia N, Xiu J, Scicchitano A, Lim B, Yee NS, Harvey HA, Gatalica Z, Reddy S.

Cancer Biol Ther. 2015 Dec 2;16(12):1726-37. doi: 10.1080/15384047.2015.1113356.


Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas.

Smaglo BG, Tesfaye A, Halfdanarson TR, Meyer JE, Wang J, Gatalica Z, Reddy S, Arguello D, Boland PM.

Oncotarget. 2015 Dec 22;6(41):43594-604. doi: 10.18632/oncotarget.6202.


Adenosquamous carcinoma of the pancreas: Molecular characterization of 23 patients along with a literature review.

Borazanci E, Millis SZ, Korn R, Han H, Whatcott CJ, Gatalica Z, Barrett MT, Cridebring D, Von Hoff DD.

World J Gastrointest Oncol. 2015 Sep 15;7(9):132-40. doi: 10.4251/wjgo.v7.i9.132. Review.


Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers.

Wen W, Chen WS, Xiao N, Bender R, Ghazalpour A, Tan Z, Swensen J, Millis SZ, Basu G, Gatalica Z, Press MF.

J Mol Diagn. 2015 Sep;17(5):487-95. doi: 10.1016/j.jmoldx.2015.04.003.


PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.

Joseph RW, Millis SZ, Carballido EM, Bryant D, Gatalica Z, Reddy S, Bryce AH, Vogelzang NJ, Stanton ML, Castle EP, Ho TH.

Cancer Immunol Res. 2015 Dec;3(12):1303-7. doi: 10.1158/2326-6066.CIR-15-0150. Epub 2015 Aug 25.


Expression of miRNAs in adenoid cystic carcinomas of the breast and salivary glands.

Kiss O, Tőkés AM, Vranic S, Gatalica Z, Vass L, Udvarhelyi N, Szász AM, Kulka J.

Virchows Arch. 2015 Nov;467(5):551-62. doi: 10.1007/s00428-015-1827-3. Epub 2015 Aug 21.


Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast.

Vranic S, Marchiò C, Castellano I, Botta C, Scalzo MS, Bender RP, Payan-Gomez C, di Cantogno LV, Gugliotta P, Tondat F, di Celle PF, Mariani S, Gatalica Z, Sapino A.

Hum Pathol. 2015 Sep;46(9):1350-9. doi: 10.1016/j.humpath.2015.05.017. Epub 2015 Jun 5.


Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.

Gatalica Z, Bilalovic N, Palazzo JP, Bender RP, Swensen J, Millis SZ, Vranic S, Von Hoff D, Arceci RJ.

Oncotarget. 2015 Aug 14;6(23):19819-25.


Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.

Millis SZ, Gatalica Z, Winkler J, Vranic S, Kimbrough J, Reddy S, O'Shaughnessy JA.

Clin Breast Cancer. 2015 Dec;15(6):473-481.e3. doi: 10.1016/j.clbc.2015.04.008. Epub 2015 Apr 28.


Immunohistochemical analysis of the natural killer cell cytotoxicity pathway in human abdominal aortic aneurysms.

Hinterseher I, Schworer CM, Lillvis JH, Stahl E, Erdman R, Gatalica Z, Tromp G, Kuivaniemi H.

Int J Mol Sci. 2015 May 18;16(5):11196-212. doi: 10.3390/ijms160511196.


Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets.

Movva S, Wen W, Chen W, Millis SZ, Gatalica Z, Reddy S, von Mehren M, Van Tine BA.

Oncotarget. 2015 May 20;6(14):12234-47.


HER2 expression status in diverse cancers: review of results from 37,992 patients.

Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R.

Cancer Metastasis Rev. 2015 Mar;34(1):157-64. doi: 10.1007/s10555-015-9552-6.


Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression.

Lipkin JS, Rizvi SM, Gatalica Z, Sarwani NE, Holder SL, Kaag M, Drabick JJ, Joshi M.

Cancer Biol Ther. 2015;16(1):28-33. doi: 10.4161/15384047.2014.972843.


Refractory angiosarcoma of the breast with VEGFR2 upregulation successfully treated with sunitinib.

Silva E, Gatalica Z, Vranic S, Basu G, Reddy SK, Voss A.

Breast J. 2015 Mar-Apr;21(2):205-7. doi: 10.1111/tbj.12380. Epub 2015 Feb 1. No abstract available.


Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases.

Gatalica Z, Millis SZ, Vranic S, Bender R, Basu GD, Voss A, Von Hoff DD.

Oncotarget. 2014 Dec 15;5(23):12440-7.


Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.

Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman DA, Xiao N, Overberg P, Rose I, Basu GD, Vranic S, Lynch HT, Von Hoff DD, Hamid O.

Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2965-70. doi: 10.1158/1055-9965.EPI-14-0654. Epub 2014 Nov 12.


Oncocytoma-like renal tumor with transformation toward high-grade oncocytic carcinoma: a unique case with morphologic, immunohistochemical, and genomic characterization.

Sirintrapun SJ, Geisinger KR, Cimic A, Snow A, Hagenkord J, Monzon F, Legendre BL Jr, Ghazalpour A, Bender RP, Gatalica Z.

Medicine (Baltimore). 2014 Oct;93(15):e81. doi: 10.1097/MD.0000000000000081.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk